![]() Presenting research conducted with leading research institutions including the Brigham and Women’s Hospital, the University of Basel, and the University of Pittsburgh, among others, these posters demonstrate the opportunity to integrate multiple biomarkers that cover disparate pathways to deliver quantitative, objective information on MS disease status as well as changes over time as a complement to conventional measures and endpoints. In posters focused on the serum based assay, the company concluded that a validated multivariate proteomic blood-based assay for MS disease activity assessments could serve as an objective, minimally invasive and cost-effective tool to enhance the standard of care for MS patients and their physicians. While not a topic of poster or presentation at this year’s ACTRIMS Forum, Octave’s third layer of insight is directed at tracking shifts and changes in symptoms and comorbidities via the integration of mobile tools, sensors and wearables. The second layer, which includes advanced and improved MRI readings and interpretation to reveal more insights at the central nervous system layer, was the topic of one poster, with an additional poster integrating Octave’s blood based biomarkers and improved MRI analyses to show the value of a holistic view of an MS patient. This includes the ability to quantitatively and objectively assess the overall disease activity of a patient while reporting on specific pathways involved with inflammation, immune modulation, neurodegeneration and myelin integrity. The first layer, which measures the patient’s underlying biology with blood based biomarkers was the topic of three posters. The Platform provides several layers of insight, two of which were the main focus of the company’s ACTRIMS posters this year. Octave is developing a Comprehensive Care Platform to provide a quantitative, objective measurement system designed to expand clinical insights in neurodegenerative disease, beginning with MS. Current tools to evaluate and manage patients are often subjective, qualitative, and inadequate to address critical questions of interest. This chronic, lifelong, debilitating disease is associated with high costs, significant variation in practice and generally poor outcomes. The posters presented by Octave Bioscience at the ACTRIMS Forum 2021 underscore the company’s commitment to the pursuit of revealing deeper clinical insights and addressing the multiple challenges and unmet needs associated with MS. The posters collectively highlight the company’s progress in developing measurement tools to address the opportunity to more accurately and precisely measure neurodegenerative diseases, such as MS, given their underlying complexity, heterogeneity and variation. Octave Bioscience (Octave), the developer of a fully integrated care management platform for multiple sclerosis (MS) and other neurodegenerative diseases, today announced the presentation of five posters at the ACTRIMS Forum 2021. MENLO PARK, Calif.-(BUSINESS WIRE)-Feb 26, 2021.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |